Immunotherapy plus chemo vs. chemo alone for advanced colorectal cancer before surgery
Treatments studied
Part of Cancer, Digestive system, Immune system & allergy clinical trials.
This trial tests whether adding immunotherapy (a treatment that helps your immune system fight cancer) to standard chemotherapy before surgery works better than chemotherapy alone for people with locally advanced colorectal cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Adults aged 18 to 75 with colorectal cancer that has not spread to other parts of the body
- Diagnosed as stage II or III colorectal cancer based on imaging scans (CT or MRI)
- Sufficient tumor tissue available for specialized testing (mismatch repair or microsatellite instability)
- No prior chemotherapy or radiation for colorectal cancer
- Good overall health (able to perform daily activities) and normal organ function
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three chemotherapy drugs (nanoliposomal irinotecan, oxaliplatin, and capecitabine) given before surgery to shrink locally advanced colorectal cancer that cannot be treated with radiation. The goal is to make the tumor removable with a better chance of complete removal (R0 resection).
This trial compares two different chemotherapy combinations given before surgery for locally advanced colon cancer. One option adds an immunotherapy drug to the chemo. The goal is to see which approach works better at shrinking the tumor and improving outcomes.
This Phase 2 trial studies giving chemotherapy plus immune therapy before surgery for certain colon cancers that do not have mismatch repair defects (MSS/pMMR). The goal is to shrink and control the tumor and improve outcomes compared with standard approaches.
This trial tests a new combination of two chemotherapy drugs (CAPOX) plus an immunotherapy drug (tislelizumab) before surgery for high-risk colon cancer that has not spread. It aims to see if adding tislelizumab helps shrink the tumor and lower the chance of the cancer coming back.
This trial tests whether giving chemotherapy followed by an immunotherapy drug (a checkpoint inhibitor) before surgery helps shrink locally advanced colon cancer. It is for people with a specific tumor type (MSS and RAS mutation) who have not had prior treatment.
This trial tests whether giving chemotherapy before surgery can improve outcomes for patients with colon cancer that has not spread to other parts of the body. The treatment aims to shrink the tumor and reduce the chance of the cancer coming back.
Hear when a new Locally Advanced Colorectal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.